Grace Therapeutics Inc. (GRCE) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Grace Therapeutics Inc. (GRCE:NASDAQ), powered by AI.

Current Price
$2.35
P/E Ratio
-3.0
Market Cap
28M
Sector
Healthcare
What is the Grace Therapeutics Inc. stock price forecast?

Grace Therapeutics Inc. is currently trading at $2.35. View real-time AI analysis on Alpha Lenz.

What is Grace Therapeutics Inc. insider trading activity?

View the latest insider trading data for Grace Therapeutics Inc. on Alpha Lenz.

What is Grace Therapeutics Inc.'s P/E ratio?

Grace Therapeutics Inc.'s P/E ratio is -3.0.

Grace Therapeutics Inc.

NASDAQ · GRCE
$2.35
Ask about Grace Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Grace Therapeutics Inc. trades at a P/E of -3.0 (undervalued) with modest ROE of -14.9%.

Ask for details

Company Overview

Grace Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments. The company specializes in creating unique drug formulations and delivery systems to address unmet medical needs, particularly in the fields of neurology and rare diseases. Notable for its research and development efforts, Grace Therapeutics aims to enhance the effectiveness and patient experience of existing drugs by altering their formulations. This approach not only seeks to improve therapeutic outcomes but also targets a reduction in side effects and enhanced patient compliance. Headquartered in the United States, Grace Therapeutics Inc. collaborates with healthcare professionals, research institutions, and regulatory bodies to bring its innovative solutions to the market. By prioritizing innovation in drug delivery systems, the company plays a critical role in advancing medical treatments and addressing significant gaps within the pharmaceutical landscape, potentially offering new hope to patients with limited treatment options.

CEOMr. Prashant Kohli
SectorHealthcare
IndustryBiotechnology
Employees6

Company Statistics

FY 2025

Profile

$28.41MMarket Cap
$0.00Revenue
0.00Shares Out
6Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-2.97P/E
0.43P/B
N/AEV/Sales
-0.32EV/EBITDA
-1.91P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-13.17%ROA
-14.91%ROE
-22.96%ROIC

Financial Health

$22.13MCash & Cash Equivalents
$-16.75MNet Debt
8.08%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Grace Therapeutics Inc. (ticker: GRCE) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 6 employees. Market cap is $28M.

The current price is $2.35 with a P/E ratio of -2.97x and P/B of 0.43x.

ROE is -14.91%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Grace Therapeutics Inc. (Healthcare) Stock Forecast & Analysis $2.35 | Alpha Lenz